DuPont de Nemours and Company
http://www.dupont.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From DuPont de Nemours and Company
Early Strides for Takeda’s Qdenga In Brazil, India Deal Adds New Dimension
Takeda’s head of multi-country organization, India and Southeast Asia, Dion Warren, tells Scrip how things are shaping for Qdenga in Brazil’s public vaccination program and outlines the contours, including pricing aspects, of the deal with Biological E for the dengue vaccine. The US IND application for the jab is still open.
Arena BioWorks Wants To Address Inefficiency Of Early R&D Finance
Backed with $500m to look into the mechanistic underpinnings of unmet medical needs, Arena BioWorks will employ a hub-and-spoke model to incubate biotechs around a central technology hub.
Newron Enters New Year With High Hopes For Evenamide
All being well, the Italian firm will soon have the results from a late-stage study of evenamide in schizophrenia patients who show an inadequate response to atypical antipsychotics.
Deal Watch: Lilly Sends European Commercial Rights For Two Migraine Drugs To Organon
Plus deals involving Biocytogen, Neurocrine and Ona, Aeterna Zentaris/Ceapro, Teva/Biolojic Design, Pathos AI/Rain Oncology, Inhibitor Therapeutics/Johns Hopkins and more.
Company Information
- Industry
- Diversified
- Other Names / Subsidiaries
-
- DowDuPont
- DuPont
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice